Redhawk Holdings's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Redhawk Holdings (IDNG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Redhawk Holdings vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-92.6% annualized vs trailing 12 months).
- Peer revenue share: Redhawk Holdings accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IDNG Sales vs. its Competitors, Q3 2021
Redhawk Holdings generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Oil And Gas Production industry grew revenue 3.2% year over year, combined, vs -80.0% for Redhawk Holdings. Redhawk Holdings's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
IDNG Stock Performance relative to its Competitors
Redhawk Holdings's Comment on Competition and Industry Peers
Many of the companies with which we aim to compete for financing and for the acquisition of medical device and branded generic pharmaceutical assets have greater financial and technical resources than those available to us. Accordingly, these competitors may be able to spend greater amounts on assets of merit or on developing and distributing their own technologies.
General competitive conditions may be substantially affected by various forms of regulation introduced from time to time by the governments of the United States and other countries, as well as factors beyond our control, including overall levels of supply and demand for the product types which we seek to distribute.
In the face of competition, we may not be successful in acquiring or successfully exploiting any distribution rights which we have acquired or may acquire in the future. Despite this, we hope to compete successfully in the medical device industry by:
maintaining low operating costs;
relying on the strength of our management’s and future sales team’s
contacts;
utilizing our team’s previous product and sales and support experience
in the specific device area; and
using our size and experience to our advantage by adapting quickly to changing
market conditions or responding swiftly to potential opportunities.
